Difference between revisions of "Profiles"
Jump to navigation
Jump to search
(3 intermediate revisions by one other user not shown) | |||
Line 21: | Line 21: | ||
::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | ::*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]] | ||
− | *[[Media:QIBA US SWS Profile | + | *[[Media:QIBA US SWS Profile 01.15.2024-clean version.pdf | US Shear Wave Speed for Liver Fibrosis 2024-01-15]] |
− | ::*[[Media:SWS Checklists-Appendix E- | + | ::*[[Media:SWS Checklists-Appendix E-12.28.2023.xlsx|Checklists - US SWS Appendix E 2023-12-28]] |
::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]] | ::*[[Media:SWS Checklists-Appendix E-01.26.2023.xlsx|US SWS Checklist for Clinically Feasible (Technical Confirmation) Site Assessment, 01.26.2023]] | ||
Line 43: | Line 43: | ||
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | *[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]] | ||
− | *[[Media:QIBA US VBF Profile | + | *[[Media:QIBA US VBF Profile 01.05.2024-Consensus.pdf | US Volume Blood Flow Profile, Consensus version 2024-01-05]] |
*[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | *[[Media:QIBA PDFF Profile Stage2 FINAL.pdf|MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | ||
Line 50: | Line 50: | ||
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles=== | ||
− | |||
− | |||
− | |||
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | *[[Media:QIBA fMRI Profile 1 PC-rev1.pdf|fMRI for Sensorimotor Mapping 2017-06-19]] (comments '''closed''' on December 31, 2017) | ||
Revision as of 17:36, 17 January 2024
Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.
Profiles may be of use at any Stage.
Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles
- CT Atherosclerosis Biomarkers 2023-03-28
- CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2023-12-19
- CT Tumor Volume Change for Advanced Disease 2022-07-21 - Streamlined Profile including Conformance Checklists
- PET/CT FDG SUV for Response to Cancer Therapy, v114, 2023-08-16, contains updated checklist
- PET/CT FDG SUV for Response to Cancer Therapy 2016-11-18
Stage 2: Consensus Profiles
- CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23
Stage 1: Public Comment Profiles
- fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)
Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.
Tools to aid Biomarker Committees in collating these comments:
- {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
- {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet
QIBA Profiles and Clinical Applications
Format for Citing Profiles
Cite QIBA Profile documents as:
- Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL
Example:
- QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
Statements of Endorsement
See Also
- How to use QIBA Profiles
- Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
- Profile Conformance describes how sites and products claim conformance to a Profile.
- QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)